scispace - formally typeset
R

Ralph B. D'Agostino

Researcher at Wake Forest University

Publications -  1336
Citations -  250792

Ralph B. D'Agostino is an academic researcher from Wake Forest University. The author has contributed to research in topics: Framingham Heart Study & Framingham Risk Score. The author has an hindex of 226, co-authored 1287 publications receiving 229636 citations. Previous affiliations of Ralph B. D'Agostino include VA Boston Healthcare System & University of Illinois at Urbana–Champaign.

Papers
More filters
Journal ArticleDOI

Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer?

TL;DR: There is no suggestion that the addition of a vaginal cuff brachytherapy boost to pelvic radiation is beneficial for pelvic control or disease-free survival for patients with Stage I or II endometrial cancer.
Journal ArticleDOI

Physical Activity and Electronic Media Use in the SEARCH for Diabetes in Youth Case-Control Study

TL;DR: Large proportions of youths with DM, especially type 2 DM, failed to meet PA and EM use recommendations, and differences in PA andEM use for DM/control groups were assessed with adjustment for age, study site, and race/ethnicity.
Journal ArticleDOI

Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage thrombolytic predictive instrument (tpi) project results

TL;DR: Excess pulse blood pressure predicted thrombolysis-related intracranial hemorrhage better than other forms of pretreatment blood pressure, perhaps better describing the pathophysiology of intrac Cranium hemorrhage, including the effect of age.
Journal ArticleDOI

Role of Smoking in the U-Shaped Relation of Cholesterol to Mortality in Men: The Framingham Study

TL;DR: The authors used data collected on 1,959 males aged 35-69 years from the fourth Framingham Study examination to analyze the relations between total serum cholesterol levels and 409 coronary deaths, 325 cancer deaths, and 534 other deaths for a 32-year follow-up.